tbuckley/cabot-search huggingface dataset:
VA Extends New Hepatitis C Drugs to All Veterans in Its Health System
Authors: Judith Graham
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Kyoto Prognostic Index for Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era
Authors: Tsutomu Kobayashi, Junya Kuroda, Isao Yokota, Kazuna Tanba, Tomohiko Taki, Takahiro Fujino, Saeko Kuwahara, Reiko Isa, Junko Yamaguchi, Eri Kawata, Teruaki Akaogi, Hitoji Uchiyama, Hiroto Kaneko, Nobuhiko Uoshima, Yutaka Kobayashi, Satoshi Teramukai, Masafumi Taniwaki
Journal: Blood (2015)
Diagnosed and Undiagnosed Diabetes Prevalence by County in the U.S., 1999–2012
Authors: Laura Dwyer-Lindgren, Johan P. Mackenbach, Frank J. van Lenthe, Abraham D. Flaxman, Ali H. Mokdad
Journal: Diabetes Care (2016)

OBJECTIVE Previous analyses of diabetes prevalence in the U.S. have considered either only large geographic regions or only individuals in whom diabetes had been diagnosed. We estimated county-level trends in the prevalence of diagnosed, undiagnosed, and total diabetes as well as rates of diagnosis and effective treatment from 1999 to 2012. RESEARCH DESIGN AND METHODS We used a two-stage modeling procedure. In the first stage, self-reported and biomarker data from the National Health and Nutrition Examination Survey (NHANES) were used to build models for predicting true diabetes status, which were applied to impute true diabetes status for respondents in the Behavioral Risk Factor Surveillance System (BRFSS). In the second stage, small area models were fit to imputed BRFSS data to derive county-level estimates of diagnosed, undiagnosed, and total diabetes prevalence, as well as rates of diabetes diagnosis and effective treatment. RESULTS In 2012, total diabetes prevalence ranged from 8.8% to 26.4% among counties, whereas the proportion of the total number of cases that had been diagnosed ranged from 59.1% to 79.8%, and the proportion of successfully treated individuals ranged from 19.4% to 31.0%. Total diabetes prevalence increased in all counties between 1999 and 2012; however, the rate of increase varied widely. Over the same period, rates of diagnosis increased in all counties, while rates of effective treatment stagnated. CONCLUSIONS Our findings demonstrate substantial disparities in diabetes prevalence, rates of diagnosis, and rates of effective treatment within the U.S. These findings should be used to target high-burden areas and select the right mix of public health strategies.
The Impact of Combination Chemotherapy and Tandem Stem Cell Transplant on Clonal Substructure and Mutational Pattern at Relapse of MM
Authors: Christoph Heuck, Niels Weinhold, Erich Allen Peterson, Michael Bauer, Caleb K. Stein, Timothy Ashby, Shweta S. Chavan, Ruslana Tytarenko, Owen W Stephens, Tobias Meissner, Donald Johann, Frits van Rhee, Sarah Waheed, Sarah K. Johnson, Maurizio Zangari, Aasiya Matin, Nathan Petty, Shmuel Yaccoby, Faith E Davies, Joshua Epstein, Bart Barlogie, Gareth J Morgan
Journal: Blood (2015)
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Authors: Nicolas Mottet, Joaquim Bellmunt, Michel Bolla, Erik Briers, Marcus G. Cumberbatch, Maria De Santis, Nicola Fossati, Tobias Gross, Ann M. Henry, Steven Joniau, Thomas B. Lam, Malcolm D. Mason, Vsevolod B. Matveev, Paul C. Moldovan, Roderick C.N. van den Bergh, Thomas Van den Broeck, Henk G. van der Poel, Theo H. van der Kwast, Olivier Rouvière, Ivo G. Schoots, Thomas Wiegel, Philip Cornford
Journal: European Urology (2016)
Trajectories of Cardiovascular Risk Factors and Incidence of Atrial Fibrillation Over a 25-Year Follow-Up
Authors: Faye L. Norby, Elsayed Z. Soliman, Lin Y. Chen, Lindsay G.S. Bengtson, Laura R. Loehr, Sunil K. Agarwal, Alvaro Alonso
Journal: Circulation (2016)

Timing and trajectories of cardiovascular risk factor (CVRF) development in relation to atrial fibrillation (AF) have not been described previously. We assessed trajectories of CVRF and incidence of AF over 25 years in the ARIC study (Atherosclerosis Risk in Communities).We assessed trajectories of CVRF in 2456 individuals with incident AF and 6414 matched control subjects. Subsequently, we determined the association of CVRF trajectories with the incidence of AF among 10 559 AF-free individuals (mean age, 67 years; 52% men; 20% blacks). Risk factors were measured during 5 examinations between 1987 and 2013. Cardiovascular events, including incident AF, were ascertained continuously. We modeled the prevalence of risk factors and cardiovascular outcomes in the period before and after AF diagnosis and the corresponding index date for control subjects using generalized estimating equations. Trajectories in risk factors were identified with latent mixture modeling. The risk of incident AF by trajectory group was examined with Cox models.The prevalence of stroke, myocardial infarction, and heart failure increased steeply during the time close to AF diagnosis. All CVRFs were elevated in AF cases compared with controls >15 years before diagnosis. We identified distinct trajectories for all the assessed CVRFs. In general, individuals with trajectories denoting long-term exposure to CVRFs had increased AF risk even after adjustment for single measurements of the CVRFs.AF patients have increased prevalence of CVRF many years before disease diagnosis. This analysis identified diverse trajectories in the prevalence of these risk factors, highlighting their different roles in AF pathogenesis.
From Choosing Wisely to Practicing Value—More to the Story
Authors: Anna L. Parks, Patrick G. O’Malley
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
The similarity and difference between ant and human ultrasocieties: From the viewpoint of scaling laws
Authors: Chen Hou
Journal: Behavioral and Brain Sciences (2016)

Complementary to Gowdy & Krall's comparison between ants and humans, I use economy scaling laws to discuss the similarity and difference between them quantitatively. I hypothesize that individual variations in society result in higher energetic efficiency in larger groups, and that the difference in the sustainability between these species originates from the driving forces of growth with different scaling powers.
Highlights of the Year in JACC 2011
Authors: Anthony N. DeMaria, Jeroen J. Bax, Ori Ben-Yehuda, Gregory K. Feld, Barry H. Greenberg, Jennifer Hall, Mark Hlatky, Wilbur Y.W. Lew, Joao A.C. Lima, Alan S. Maisel, Sanjiv M. Narayan, Steven Nissen, David J. Sahn, Sotirios Tsimikas
Journal: Journal of the American College of Cardiology (2012)
Voluntary Self-Exclusion to Reduce Transmission of AIDS by Blood Transfusion-Reply
Authors: Neal A. Halsey
Journal: JAMA (1987)

<h3>In Reply.—</h3> We fully agree with Kalish and coworkers that it is "imperative to use all possible methods to remove high-risk donors from the population prior to testing." We did not, in any way, intend to denigrate the importance of voluntary self-exclusion in assuring a safe blood supply, and our conclusion, as stated at the end of our letter to the editor, was that "requests for voluntary self-exclusion, alone, were not sufficient to ensure a safe blood supply." The important word in that conclusion is, of course, "alone." We fully agree with Kalish and colleagues that self-exclusion is an integral part of ensuring a safe blood supply and must be continued. Kalish et al also point out that our study did not "address the issue of voluntary self-deferral by asymptomatic high-risk donors." Our study, by its nature, required that we review the blood donation records only of individuals who were
Cancer patients’ views on adherence to advance directives
Authors: S. W. Sahm, R. Will, G. Hommel
Journal: Journal of Clinical Oncology (2005)

8068 Background: Advance directives are propagated to promote patients’ autonomy at the end of life. It has never been studied whether cancer patients are inclined to accept this instrument as a means for decision-making at the end of life. Cancer patients’ and healthy persons’ attitudes towards adherence to advance directives because that is (or is not), the right thing to do“, not because they are legally obliged to do so, were studied and compared with that of medical staff. Methods: In a vignette study using a structured questionnaire 5 cases were presented in which a decision has to be made whether instructions laid down in an advance directive are to be followed. As an endpoint an adherence score was calculated (maximum value 5). To compare frequency of answers and the association with categorical variables chi-square-test was used. The comparison of the frequency of ordinal variables in the groups, their correlation with categorical variables, and the comparison of the score was done using the Wilcoxon or Kruskal-Wallis test for non-parametric distributions. Results: 400 Cancer patients, healthy persons, nursing staff and physicians (n=100 in each group) were interviewed. The adherence score is low in all groups, yet is lowest in patients (1.55; standard deviation 1.13) and healthy controls (1.60; 1.37). The scores differ significantly between nursing staff (2.05; 1.29) on the one hand und patients and healthy controls on the other (p<0.005 and p< 0.05 respectively), and between doctors (1.87; 1.04) and patients (p<0.05). The difference between doctors and healthy controls shows a tendency only (p=0,06). More people who live alone and those who have already written an advance directive want these documents to be followed. Conclusions: Cancer patients and healthy persons widely disregard instructions laid down in advance directive. They consider advance directive less binding than physicians and nursing staff. Only few interviewees want dvance directives to be followed strictly. Of this minority most live alone or have already written one. To improve decision-making at the end of life for a majority of cancer patients who are no longer able to decide for themselves, alternative concepts should be considered. No significant financial relationships to disclose.
Immunotherapy with dendritic cells as a second-line therapy in advanced pleural mesothelioma.
Authors: J. Nesselhut, D. Marx, R. Y. Chang, D. Lorenzen, N. Cillien, W. Goebel, F. Fändrich, T. Nesselhut
Journal: Journal of Clinical Oncology (2010)

e13063 Background: Malignant pleural mesothelioma (MPM) is an aggressive disease with an unfavorable prognosis. The current front-line treatment for nonoperable stages is cisplatinum in combination with pemetrexed chemotherapy. The reported median overall survival times are less than 15 months. After failure of first-line therapy there is currently no proven effective therapy, whereas potential side effects from further treatments may impair quality of life. In those cases, we report that immunotherapy with monocyte-derived dendritic cells (MoDC) can be effective without significant impact on life quality. Methods: After isolating monocytes from peripheral blood of n=14 patients with stage 4 MPM who failed first-line chemotherapy, MoDC were generated using standard protocols. The MoDC were primed on day 5 with tumor-lysate and co-cultured with toll-like receptor ligands to induce a TH1-polarization of the MoDC. In one case, an allogeneic cell line lysed by the oncolytic Newcastle disease virus (NDV) was used. This patient received an NDV injection one day before the DC administration. In general, the MoDC were harvested on day 7 and administered to the patients, intradermally. Results: We were able to induce a clinical response in 29% of the patients (n=3 stabilization, 1 partial remission). The median survival after onset of DC-therapy was 7 months (1-26 months) and 24 months (7-33 months) after primary diagnosis. The therapy was well tolerated without having any major side effect. Interestingly, the patient showing a partial remission received the NDV-modified vaccine. IFN-gamma Elispot analyses from patients who received NDV injections and NDV-modified MoDC show that MoDC primed with NDV-lysed tumor cells can induce a specific CD4 and CD8 T-cell response against the NDV-lysed tumor cells whereas healthy donors show no specific T-cell response. Conclusions: Immunotherapy with dendritic cells may prolong the overall survival of patients with MPM after failure of first-line therapy without significant impact on the quality of life. For the first time, we demonstrated that NDV is able to infect MPM cells, leading to lysis of these cells. No significant financial relationships to disclose.
Sustained low rotavirus activity and hospitalisation rates in the post-vaccination era in Belgium, 2007 to 2014
Authors: Martine Sabbe, Nicolas Berger, Adriaan Blommaert, Benson Ogunjimi, Tine Grammens, Michiel Callens, Koen Van Herck, Philippe Beutels, Pierre Van Damme, Joke Bilcke
Journal: Eurosurveillance (2016)

In 2006, Belgium was the first country in the European Union to recommend rotavirus vaccination in the routine infant vaccination schedule and rapidly achieved high vaccine uptake (86–89% in 2007). We used regional and national data sources up to 7 years post-vaccination to study the impact of vaccination on laboratory-confirmed rotavirus cases and rotavirus-related hospitalisations and deaths. We showed that (i) from 2007 until 2013, vaccination coverage remained at 79–88% for a complete course, (ii) in children 0–2 years, rotavirus cases decreased by 79% (95% confidence intervals (CI): 68–­89%) in 2008–2014 compared to the pre-vaccination period (1999–­2006) and by 50% (95% CI: 14–82%) in the age group ≥ 10 years, (iii) hospitalisations for rotavirus gastroenteritis decreased by 87% (95% CI: 84–90%) in 2008–­2012 compared to the pre-vaccination period (2002–­2006), (iv) median age of rotavirus cases increased from 12 months to 17 months and (v) the rotavirus seasonal peak was reduced and delayed in all post-vaccination years. The substantial decline in rotavirus gastroenteritis requiring hospitalisations and in rotavirus activity following introduction of rotavirus vaccination is sustained over time and more pronounced in the target age group, but with evidence of herd immunity.
Abstract 2700: The IAP inhibitor Debio 1143 reverses carboplatin resistance in ovarian cancer cells by inducing both apoptosis and necroptosis
Authors: Benoît Thibault, Ludivine Genre, Clothilde Broca, Maryse Barbier, Claudio Zanna, Grégoire Vuagniaux, Jean-Pierre Delord, Bettina Couderc
Journal: Cancer Research (2015)

Abstract Ovarian cancer remains the most lethal gynecological cancer. The efficacy of conventional chemotherapy with a combination of platinum salts and taxanes is transient because 70 to 80% of patients initially responding to platinum finally relapse. Mechanisms of resistance to carboplatin include a disruption of the balance between key pro-and anti-apoptotic proteins such as the inhibitor of apoptosis protein (IAP) family. Drug mimetics of the endogenous IAP inhibitor SMAC constitute a novel therapeutic approach to overcome apoptosis resistance and are currently in clinical development for cancer treatment. In this study we tested the ability of the oral IAP inhibitor Debio 1143 to revert carboplatin resistance in three carboplatin-sensitive (OVCAR-3, IGROV-1, A2780S) and three carboplatin-resistant (SKOV-3, A2780R, EFO-21) human ovarian tumor cell lines. We demonstrated that in vitro Debio 1143 was able to sensitize SKOV-3, EFO-21 and A2780R ovarian tumor cells to carboplatin. In addition, we demonstrated that the combination allowed a full recovery of carboplatin sensitivity in A2780R similar to the sensitive cell line A2780S. The sensitization to carboplatin correlated with an increased induction of apoptosis (Annexin V/PI assay and PARP cleavage) in SKOV-3 and A2780R cells. In EFO-21 cells, Debio 1143 triggered necroptosis as shown by the necroptosis inhibitor necrostatin-1 which was able to suppress Debio 1143-induced cell death with or without carboplatin. Our study shows that in the above human ovarian tumor cell lines Debio 1143 induces degradation of cIAP1 while XIAP levels remain unchanged. Using a carboplatin-resistant in vivo ovarian tumor mouse model, we further showed that Debio 1143 alone or in combination with carboplatin causes marked regression of subcutaneous SKOV-3 tumors. Together, our results suggest that Debio 1143 in combination with carboplatin could provide considerable benefit to patients with innate or acquired resistance to carboplatin by acting as a sensitizing agent. Debio 1143 is currently evaluated in combination with carboplatin and paclitaxel in patient with advanced solid malignancies including platinum-refractory ovarian cancer (NCT01930292). Citation Format: Benoît Thibault, Ludivine Genre, Clothilde Broca, Maryse Barbier, Claudio Zanna, Grégoire Vuagniaux, Jean-Pierre Delord, Bettina Couderc. The IAP inhibitor Debio 1143 reverses carboplatin resistance in ovarian cancer cells by inducing both apoptosis and necroptosis. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2700. doi:10.1158/1538-7445.AM2015-2700
High Complete Remission Rate in Patients with Acute Myeloid Leukemia (AML) above the Age of 60 Years: A Report of the AML97#38 Study of the East German Hematology and Oncology Study Group.
Authors: Cornelia Becker, Haifa Al Ali, Rainer Krahl, Wolfram Poenisch, Ulrich Wedding, Ferdinand Fiedler, Rita Pasold, Matthias Freund, Rita Subert, Dietrich Kaempfe, Johannes Meran, Manfred Herold, Norma Peter, Wolfgang Knauf, Erika Kettner, Wolfgang Schultze, Klaus Dachselt, Hans Heinrich Wolf, Ute Kreibich, Manfred Schulze, Thomas Ittel, Michael Assmann, Norbert Grobe, Renate Huhn, Juergen Steglich, Veronika Schirmer, Christian Klinkenstein, Bernhard Opitz, Cornelia Winkelmann, Ursula Haak, Werner Helbig, Dietger Niederwieser
Journal: Blood (2004)
miRNA Profiling of B Cell Subsets: Specific miRNA Profile for Germinal Center B Cells with a Marked Variation Between Centroblast and Centrocytes.
Authors: Lu Ping Tan, Miao Wang, Jan-Lukas Robertus, Rikst Nynke Schakel, Johan H Gibcus, Arjan Diepstra, Geert Harms, Suat Cheng Peh, Rogier M Reijmers, Steven T Pals, Lydia Visser, Philip Kluin, Sibrand Poppema, Bart-Jan Kroesen, Anke van den Berg
Journal: Blood (2008)
Nonneoplastic Neuroma After Radical Prostatectomy Is Not a Mimicker of Lymph Node Metastases on 68Ga–PSMA Ligand PET/CT
Authors: Thorsten Derlin, Udo Schumacher, Frank M. Bengel
Journal: Clinical Nuclear Medicine (2016)

Traumatic neuroma is frequently observed after surgery. PSMA expression has been demonstrated in neoplastic nerve sheath tumors, which may mimic metastases on PSMA imaging. In this case, histopathologic evaluation of a pelvic lesion with assumed intense tracer uptake on 68Ga-PSMA ligand PET/CT in a patient with biochemical recurrence of prostate cancer revealed an amputation neuroma. However, immunohistochemical evaluation showed absent PSMA expression, and follow-up PET confirmed persistence of the metastasis. Unlike neoplastic nerve sheath tumors, traumatic neuroma does not show PSMA expression and is not a mimicker of metastases on 68Ga-PSMA PET/CT.
Serum nonprotein-bound iron in testicular cancer patients treated with BEP chemotherapy.
Authors: N. I. Weijl, P. Willemse, J. Van Steijn-Van Tol, R. Kolb, K. Burggraaf, S. Osanto
Journal: Journal of Clinical Oncology (2010)

e13148 Background: The prognosis of testicular cancer (TC) patients is excellent. Curative chemotherapy leads to survival of men now at risk for chemotherapy-related long-term morbidity. Cisplatin-induced toxicity has been shown to be mainly caused by oxidative damage. Previously we have shown that the redox-active nonprotein-bound iron (NPBI) is detectable during cisplatin-based chemotherapy. This led us to evaluate the kinetics of NPBI during first-line chemotherapy in an homogeneous group of patients consisting of TC patients. Methods: We studied 26 metastatic TC patients (median age 37 years) undergoing cisplatin-based chemotherapy. Twenty-four patients received the BEP regimen (cisplatin 20 mg/m2 day 1-5, etoposide 100 mg/m2 day 1-5, bleomycin 30 I-USP day 2, 8, and 15, q 21d), of which 3 also received paclitaxel (175 mg/m2 on day 3). Two patients received cisplatin and etoposide without bleomycin. Baseline and 19 serial blood collections were performed during the first and second chemotherapy cycle for iron parameter measurements. Results: Within hours after the start of chemotherapy, a rise in total iron and NPBI occurred in individual patients. At 24 hr after the start of chemotherapy a significant peak in total iron, iron saturation, and appearance of NPBI were observed (p values < 0.05). Elevated iron and NPBI levels were sustained during days 2-4 of cycle 1. At day 8, iron parameters returned to baseline values but changed again after bleomycin infusion. During cycle 2, similar changes in iron parameters were observed. Conclusions: (B)EP chemotherapy regimen in TC patients is accompanied by marked increase in serum iron and NPBI appearance, possibly contributing to toxicity through oxidative cellular injury. Since the majority of TC patients will be cured, further studies are warranted to establish the role of NPBI in acute and long-term morbidity. No significant financial relationships to disclose.